<DOC>
	<DOCNO>NCT01630200</DOCNO>
	<brief_summary>Chronic obstructive pulmonary disease associate low grade systemic inflammatory process . Systemic inflammation hypothesize maintain cardiovascular morbidity mortality COPD . Early change vascular integrity detect via marker subclinical atherosclerosis . Selective Inhibition phosphodiesterase subtype 4 describes promise therapeutic option COPD beneficial impact lung function exacerbation rate . Moreover , anti-inflammatory effect phosphodiesterase-4 inhibition confirm recent data . The aim study assess effect phosphodiesterase-4 inhibitor Roflumilast firstly surrogates subclinical atherosclerosis secondly marker systemic inflammation peripheral circulation patient stable chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>Effects ROFLUMILAST Subclinical Atherosclerosis Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Over 40 year age Smoking history least 10 pack year Chronic obstructive pulmonary disease GOLDstage II IV diagnose accord standard criterion ( 18 ) History least one COPD exacerbation require systemic corticosteroid treatment hospitalisation previous year Insufficient compliance study medication ( â‰¤70 % tablet use ) 4 week runin period History acute exacerbation 4 week prior runin period Diagnosis alpha1antitrypsin deficiency Diagnosis asthma Acute respiratory infection ( e.g . pneumonia ) Severe acute infectious disease ( e.g . active hepatitis , HIV ) Lung cancer Bronchiectasis Interstitial lung disease Any relevant lung disease Acute myocardial infarction Systolic leave ventricular dysfunction Congestive heart failure New York Heart Association Functional Classification ( NYHA ) severity grade IV Haemodynamically significant cardiac arrhythmias heart valve deformation Peripheral arterial occlusive disease Acute chronic renal/hepatic failure Active malignancy Autoimmune disease Pregnant breastfeed woman Women use willing use adequate contraceptive measure duration trial Hypersensitivity study medication placebo Severe psychiatric neurological disorder history depression associate suicidal ideation behaviour Galactose intolerance , lactase insufficiency glucosegalactose malabsorption</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>COPD</keyword>
	<keyword>comorbidity</keyword>
	<keyword>arterial stiffness</keyword>
	<keyword>roflumilast</keyword>
</DOC>